What cancers or diseases are the main indications for Erdafitinib?

Erdafitinib is an oral fibroblast growth factor receptor (FGFR) kinase inhibitor, mainly used to treat malignant tumors harboring FGFR gene mutations or fusions. Its primary indication is for patients with urothelial cancer (especially bladder cancer), especially those with advanced or metastatic urothelial cancer who have received at least one prior therapy and in whom FGFR2 or FGFR3 gene mutations or fusions have been detected. Erdafitinib blocks the growth and spread of tumor cells by inhibiting the abnormally activated FGFR signaling pathway.

In addition to urothelial cancer, erdafitinib has also shown potential in other FGFR related solid tumors. For example, some patients with cholangiocarcinoma, lung cancer, breast cancer and other solid tumors have FGFR gene alterations, and the efficacy of erdafitinib in these patients is being continuously evaluated and verified through clinical trials. Although not all of these indications are currently approved, erdafitinib provides a new direction for the treatment of multiple FGFR mutation-driven tumors.

In patients with urothelial cancer, traditional chemotherapy has limited effect and strong drug resistance. The emergence of erdafitinib provides a new targeted treatment option for these patients. Screening patients suitable for erdafitinib through genetic testing can achieve precision medicine and improve treatment effects and patient survival rates. The introduction of erdafitinib has significantly improved the diversity and individualization of treatment options for patients with advanced urothelial cancer.

To sum up, the main indication of erdafitinib is patients with advanced urothelial cancer carrying FGFR2 or FGFR3 gene mutations or fusions, and it also shows potential in the treatment of multiple other FGFR-related tumors. With the accumulation of more clinical data, erdafitinib is expected to expand its scope of indications and become an important drug in the field of targeted therapy.

Reference link:https://www.balversa.com/